Lilly is also running two other trials with eloralintide plus tirzepatide, including another mid-stage study in obese and overweight type 2 diabetes patients, with an initial completion date in June 2026, and a Phase I trial in nondiabetic individuals, scheduled to complete in October 2025
Comprehensive lipedema management requires a multimodal approach tailored to individual patient needs, disease stage, and concurrent conditions
Miller RA, Harrison DE, Astle CM, Fernandez E, Flurkey K, Han M, Javors MA, Li X, Nadon NL, Nelson JF, Pletcher S, Salmon AB, Sharp ZD, Van Roekel S, Winkleman L, Strong R
J Mol Med 95(3):323333 James R, Kesturu G, Balian G, Chhabra A (2008) Tendon: biology, biomechanics, repair, growth factors, and evolving treatment options